SAN DIEGO, May 26, 2011 /PRNewswire/ — Amylin Pharmaceuticals,
Inc. (NASDAQ:
AMLN) (“Amylin” or “the Company”) today announced that the
United States District Court for the Southern District of
California issued a temporary restraining order (TRO) against Eli
Lilly and Company (NYSE:
LLY) (“Lilly”) relating to its litigation with respect to the
Amylin / Lilly diabetes collaboration agreement.
The U.S. District Court restrained Lilly from proceeding with
its plans to use the same sales force to sell both exenatide and
Boehringer Ingelheim GmbH’s competitive linagliptin. The
court also enjoined Lilly from disclosing any confidential
information about exenatide to any of its sales representatives or
employees participating in the marketing, promotion or sale of
linagliptin.
The complete order is being filed today on Amylin’s Current
Report on Form 8-K with the Securities and Exchange Commission.
In 2002, Amylin entered an alliance with Lilly for the global
development and commercialization of exenatide, a medicine
indicated as a first line treatment for type 2 diabetes that is
currently marketed as BYETTA® (exenatide) injection.
Exenatide is also the active ingredient in BYDUREON™
(exenatide extended-release for injectable suspension), a
once-weekly version currently under review by the FDA.
About BYETTA® (exenatide) injection
BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor
agonist to be approved by the FDA for the treatment of type 2
diabetes. BYETTA exhibits many of the same effects as the human
incretin hormone GLP-1. GLP-1 improves blood sugar after food
intake through multiple effects that work in concert on the
stomach, liver, pancreas and brain.
BYETTA is an injectable prescription medi
‘/>”/>
SOURCE
